The κλ body platform [39] was used to generate a human CEACAM5xCD3 TCB selectively targeting CEACAM5 on tumor cells and CD3 on T-cells for the treatment of CEACAM5-positive solid cancers. This evidence concerns the gene CEACAM5 and neoplasm.